Möchten Sie immer auf dem neuesten Stand bleiben?

NEWARK, Calif., Oct. 18, 2017 (GLOBE NEWSWIRE) -- Depomed, Inc. (NASDAQ:DEPO) today announced that Santosh J. Vetticaden, M.D., Ph.D., has joined Depomed as Senior Vice President, Chief Medical and...

NEWARK, Calif., Oct. 10, 2017 (GLOBE NEWSWIRE) -- Depomed, Inc. (NASDAQ:DEPO) today provided information on the impact of Hurricane Maria to the supply of NUCYNTA® ER, which is manufactured in...

NEWARK, Calif. , Sept. 05, 2017 (GLOBE NEWSWIRE) -- Depomed, Inc. (NASDAQ:DEPO) today announced that its senior management will participate in a fireside chat at the 2017 Morgan Stanley Global...

NEWARK, Calif., Aug. 28, 2017 (GLOBE NEWSWIRE) -- Depomed Inc. (NASDAQ:DEPO) today announced that it has been selected to join the Collaborative for Effective Prescription Opioid Policies (CEPOP) a...

- Updates Full-Year Financial Guidance - - Second Quarter Revenues of $100 million - - Increases Neurology Salesforce Effective September 1 - - Conference Call Scheduled for Today at 4:30 PM EDT;...

NEWARK, Calif., July 31, 2017 (GLOBE NEWSWIRE) -- Depomed, Inc. (NASDAQ:DEPO) today announced that it will release second quarter fiscal year 2017 financial results on Monday, August 7, 2017, after...

NEWARK, Calif., July 13, 2017 (GLOBE NEWSWIRE) -- Depomed Inc. (NASDAQ:DEPO) (the “Company”) today announced that it is seeking to refinance its existing $375 million principal amount of privately...

NEWARK, Calif., May 22, 2017 (GLOBE NEWSWIRE) -- Depomed, Inc. (Nasdaq:DEPO) today announced that following a comprehensive review of the Company's corporate governance practices, the Board of...

NEWARK, Calif., May 16, 2017 (GLOBE NEWSWIRE) -- Depomed, Inc. (NASDAQ:DEPO) today announced that members of senior management will participate in a fireside chat at the 2017 UBS Global Healthcare...

- First Quarter GAAP Revenues of $90 million, non-GAAP Revenues of $95 million -- Company Announces Implementation of Strategic Initiatives to Drive Portfolio Growth  -- 2017 Non-GAAP Revenue...